Portfolio

Current Investments


Cristal Therapeutics B.V.

Developing the next generation of nanomedicines.


InteRNA Technologies B.V.

Development of therapies based on the unique functions of miRNAs with a focus on oncology.


Inthera Bioscience AG

Tackling “undruggable” targets with small molecule inhibitors of intracellular protein-protein interactions.


Macrophage Pharma Ltd.

A new therapeutic approach in immune-oncology, targeting the tumor microenvironment.


Mimetas B.V.

A leading Organ-on-a-Chip Company developing human tissue and disease models for tomorrow’s medicines, chemicals and food.


Modra Pharmaceuticals B.V.

Switching from intravenous-to-oral cancer treatment.


ORCA Therapeutics B.V.

Oncolytic adenovirus technologies.


Sapreme Technologies B.V.

Enabling endosomal escape of macromolecule therapeutics.


Exited Portfolio Companies


ISA Pharmaceuticals B.V.

Fully synthetic therapeutic vaccines against cancer and persistent viral infections.


Merus N.V. – NASDAQ: MRUS

Bispecific antibodies which are targeting solid tumors and blood tumors.


Syntarga B.V.

Antibody Drug Conjugate Technologies.


News & Events